• Users Online: 328
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2018  |  Volume : 19  |  Issue : 2  |  Page : 134-139

Evaluation of topical α-2 agonist in the treatment of mixed diabetic maculopathy


Departments of Ophthalmology, Faculty of Medicine, Zagazig University, Zagazig, Egypt

Correspondence Address:
Basem M Ibrahim
Department of Ophthalmology, Faculty of Medicine, Zagazig University, Zagazig 44519
Egypt
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/DJO.DJO_77_17

Rights and Permissions

Purpose To evaluate the efficacy of topical α-2 agonist (brimonidine) in the treatment of mixed diabetic maculopathy (with edema and ischemia). Design This is a prospective randomized case series. Patients and methods Thirty eyes of 30 patients were included in this study. All eyes had mixed diabetic maculopathy as diagnosed by fluorescein angiography and spectral domain optical coherence tomography. The cases were divided into two groups: group I (15 eyes) was treated by intravitreal triamcinolone injection and topical brimonidine twice daily for 3 months, and group II (15 eyes) was treated only by intravitreal triamcinolone injection. Visual acuity, fluorescein angiography, and optical coherence tomography were done for all patients before the beginning of the treatment and every month for 3 months to detect the changes in logarithm of minimal angle of resolution (logMAR) visual acuity and the changes in the size of the foveal avascular zone and macular thickness. Results The mean logMAR visual acuity improved from 0.9±0.012 to 0.4±0.1 in group I and from 0.8±0.1 to 0.5±0.02 in group II after 3 months of treatment, with a statistically significant difference between the two groups (P=0.01). The mean central macular thickness improved from 475±25 to 395±11 μm in group I and from 480±14 to 387±9 μm in group II after 3 months of treatment, with no statistically significant difference between the two groups (P=0.5). There was more improvement in the size of the foveal avascular zone with fewer disturbances of its edges in group I when compared with group II throughout the follow-up period. The mean intraocular pressure after 3 months of treatment was 11.5±0.1 mmHg in group I and 18.5±0.02 mmHg in group II, with a significant difference between the two groups (P=0.01). Conclusion α-2 Agonist (brimonidine) has a role in the treatment of mixed diabetic maculopathy.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed12    
    Printed0    
    Emailed0    
    PDF Downloaded8    
    Comments [Add]    

Recommend this journal